---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-017546"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:38:39.201396+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics reports FY2025 product/royalty rev $831M, beats guidance; Sephience Q4 rev $92M

## Summary
- Full-year 2025 product/royalty revenue $831M, exceeding guidance; total revenue $1.73B (includes $998M Novartis collaboration).
- Sephience launch strong: Q4 rev $92M ($81M US), 946 patients on therapy; full-year rev $111M.
- Net income $682.6M for FY2025 vs net loss $363.3M in FY2024; cash $1.95B as of Dec 31.
- Sold Evrysdi royalty to Royalty Pharma for $240M upfront + up to $60M milestones; retains $150M Roche milestone.
- 2026 guidance: product rev $700-800M (19-36% growth); Phase 3 HD trial INVEST-HD to start 1H 2026.

## SEC filing metadata
- accession: 0001104659-26-017546
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/0001104659-26-017546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-017546
- JSON: https://secwatch.observer/filing/0001104659-26-017546.json
- Plain text: https://secwatch.observer/filing/0001104659-26-017546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.